Literature DB >> 24820309

Loss of Stat1 decreases megakaryopoiesis and favors erythropoiesis in a JAK2-V617F-driven mouse model of MPNs.

Adrian Duek1, Pontus Lundberg1, Takafumi Shimizu1, Jean Grisouard1, Axel Karow1, Lucia Kubovcakova1, Hui Hao-Shen1, Stephan Dirnhofer2, Radek C Skoda1.   

Abstract

The interferon-γ (IFNγ)/signal transducer and activator of transcription 1 (Stat1) pathway shows higher activity in patients with essential thrombocythemia (ET) than in polycythemia vera (PV) and was proposed to be promoting the ET phenotype. We explored the phenotypic consequences of Stat1 deficiency on the effects of Janus kinase 2 (JAK2)-V617F in vivo by crossing mice expressing JAK2-V617F with Stat1 knockout mice. JAK2-V617F;Stat1(-/-) double transgenic mice showed higher red cell parameters and lower platelet counts compared with JAK2-V617F;Stat1(+/+) mice. Bone marrow transplantation reproduced these phenotypic changes in wild-type recipients, demonstrating that the effect of Stat1 is cell-intrinsic and does not require a Stat1-deficient microenvironment. Deletion of Stat1 increased burst-forming unit-erythroid and reduced colony-forming unit-megakaryocyte colony formation driven by JAK2-V617F, but was not sufficient to completely normalize the platelet count. Gata1, a key regulator of megakaryopoiesis and erythropoiesis, was decreased in Stat1-deficient platelets. V617F transgenic mice with thrombocytosis had higher serum levels of IFNγ than normal controls and patients with ET showed higher IFNγ serum levels than patients with PV. Together, these results support the concept that activating Stat1 in the presence of JAK2-V617F, for example, through IFNγ, constrains erythroid differentiation and promotes megakaryocytic development, resulting in ET phenotype.
© 2014 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24820309     DOI: 10.1182/blood-2013-07-514208

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  13 in total

Review 1.  Novel insights into the biology and treatment of chronic myeloproliferative neoplasms.

Authors:  Tariq I Mughal; Tiziano Barbui; Omar Abdel-Wahab; Robert Kralovics; Catriona Jamieson; Hans-Michael Kvasnicka; Ann Mullaly; Raajit Rampal; Ruben Mesa; Jean-Jacques Kiladjian; Michael Deininger; Josef Prchal; Rüdiger Hehlmann; Giuseppe Saglio; Richard A Van Etten
Journal:  Leuk Lymphoma       Date:  2014-11-19

Review 2.  SOHO State-of-the-Art Update and Next Questions: MPN.

Authors:  Prithviraj Bose; Jason Gotlib; Claire N Harrison; Srdan Verstovsek
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2018-01

Review 3.  Oncogenic Drivers in Myeloproliferative Neoplasms: From JAK2 to Calreticulin Mutations.

Authors:  Xavier Cahu; Stefan N Constantinescu
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 3.952

Review 4.  Overview of Transgenic Mouse Models of Myeloproliferative Neoplasms (MPNs).

Authors:  Andrew Dunbar; Abbas Nazir; Ross Levine
Journal:  Curr Protoc Pharmacol       Date:  2017-06-22

Review 5.  Novel targets to cure primary myelofibrosis from studies on Gata1low mice.

Authors:  Maria Zingariello; Fabrizio Martelli; Paola Verachi; Claudio Bardelli; Francesca Gobbo; Maria Mazzarini; Anna Rita Migliaccio
Journal:  IUBMB Life       Date:  2019-11-21       Impact factor: 3.885

6.  STAT1 activation in association with JAK2 exon 12 mutations.

Authors:  Anna L Godfrey; Edwin Chen; Charles E Massie; Yvonne Silber; Francesca Pagano; Beatriz Bellosillo; Paola Guglielmelli; Claire N Harrison; John T Reilly; Frank Stegelmann; Fontanet Bijou; Eric Lippert; Jean-Michel Boiron; Konstanze Döhner; Alessandro M Vannucchi; Carlos Besses; Anthony R Green
Journal:  Haematologica       Date:  2015-12-03       Impact factor: 9.941

7.  Deletion of Stat3 enhances myeloid cell expansion and increases the severity of myeloproliferative neoplasms in Jak2V617F knock-in mice.

Authors:  D Yan; F Jobe; R E Hutchison; G Mohi
Journal:  Leukemia       Date:  2015-05-18       Impact factor: 11.528

8.  Mediator Kinase Phosphorylation of STAT1 S727 Promotes Growth of Neoplasms With JAK-STAT Activation.

Authors:  Ioana I Nitulescu; Sara C Meyer; Qiang Jeremy Wen; John D Crispino; Madeleine E Lemieux; Ross L Levine; Henry E Pelish; Matthew D Shair
Journal:  EBioMedicine       Date:  2017-11-21       Impact factor: 8.143

Review 9.  Molecular pathogenesis of the myeloproliferative neoplasms.

Authors:  Graeme Greenfield; Mary Frances McMullin; Ken Mills
Journal:  J Hematol Oncol       Date:  2021-06-30       Impact factor: 17.388

Review 10.  Recent advances in understanding myelofibrosis and essential thrombocythemia.

Authors:  William Vainchenker; Stefan N Constantinescu; Isabelle Plo
Journal:  F1000Res       Date:  2016-04-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.